To date, published real-world data on the prognostic factors of patients with ALK-positive advanced NSCLC in Spain are limited. We aim to evaluate the effect of number of metastases (M1) organs on overall survival (OS) in a multicenter cohort of Spanish ALK-positive NSCLC p diagnosed between 2008 and 2017. We included p with stage IV at diagnosis since 2011 to April 2018. OS was worse with increased metastatic sites involved at diagnosis in p with ALK positive NSCLC, being liver M1 associated with the highest risk of mortality. Brain metastases at diagnosis were not a prognostic factor for OS in our series. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.808
Authors: L. Angelats, R. Garcia Campelo, R. Bernabe, E. Arriola, P. Rocha, V. Calvo De Juan, E. Sais, A. Barba, N. Viñolas, M. Gil Moreno, L. Vilà, O. Juan, N. Vilariño, M. Cobo, M. Domine, S. Vazquez, J. Coves, R. Marse-Fabregat, A.M. Esteve Gomez, E. Carcereny